Stay updated with breaking news from Steve glover. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating)’s stock price shot up 6.5% during trading on Monday . The stock traded as high as $8.41 and last traded at $8.39. 124,121 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,107,739 shares. The stock had previously closed at $7.88. […]
Should You Buy or Sell Coherus BioSciences Stock? Get The Latest CHRS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Sargent Investment Group LLC trimmed its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) by 26.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,200 shares of the biotechnology company’s stock after selling 3,970 shares during the period. Sargent Investment Group LLC’s holdings in […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) were down 3.1% on Tuesday . The company traded as low as $7.58 and last traded at $7.60. Approximately 218,070 shares traded hands during trading, a decline of 81% from the average daily volume of 1,132,020 shares. The stock had previously closed at $7.84. Analysts Set […]
Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent ratings […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating)’s share price traded up 6.6% during trading on Monday . The company traded as high as $7.33 and last traded at $7.29. 473,528 shares were traded during trading, a decline of 58% from the average session volume of 1,136,560 shares. The stock had previously closed at $6.84. Analysts […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily trading volume, of 1,260,000 shares, […]